Clinician (Oncology / Hematology)

Micro1; India; Remote; INR 900,000 - 1,300,000; Part time

Job summary

Cashback24x7 seeks a Clinician (Oncology/Hematology) for a remote contractor role to contribute to AI-enabled healthcare projects. You will apply deep domain expertise to train next-generation AI systems through high-quality clinical input, with no prior AI experience required.

The role emphasizes clinical judgment, accuracy in evaluating efficacy/safety endpoints, and clear, structured explanations for non-clinical readers. Prior involvement in trials or medical monitoring is valued.

Qualifications

• Specialist registration or board certification in medical oncology and/or haematology.
• 5+ years of post-training clinical experience in oncology/haematology.
• Direct involvement in clinical trials or monitoring roles.

Responsibilities

• Author and review evaluation tasks with clinical judgment across oncology/haematology.
• Assess efficacy/safety endpoints for clinical significance.
• Apply judgment to dose escalation, toxicity, and adverse event attribution.
• Evaluate benefit-risk reasoning and durability of conclusions with new data.
• Flag clinically implausible content and maintain coherence of narratives.
• Provide structured, guideline-based rationales for non-clinical audiences.

Skills

Clinical judgment

Regulatory knowledge

CTCAE grading

RECIST

Lugano

IMWG

IWCLL

ELN

ORR

DoR

PFS

OS

MRD

Written communication

Clinical study reports

Education

Board certification in medical oncology/haematology

Tools

Investigator brochures

CSRs

Protocols

Job description

Job Description

Role Title: Clinician (Oncology / Hematology)

Role Type: Contractor

Location: Remote

micro1 is engaging Clinician (Oncology / Hematology)s to contribute to a customer’s project at the forefront of AI in healthcare. In this role, you'll apply your expertise to help train next-generation AI systems. Your work will shape how models learn, reason, and perform through high-quality, real-world input. No prior experience in AI is required — your domain knowledge is what matters.

Scope of Work

• Author and review evaluation tasks that require nuanced clinical judgment, leveraging Clinical Study Reports, periodic safety reports, and regulatory correspondence in oncology and haematology.
• Assess the clinical defensibility of efficacy and safety conclusions, ensuring endpoints and effect sizes reflect true clinical significance.
• Apply advanced judgment to dose escalation, dose-limiting toxicity, modifications, adverse event grading and attribution, and the coherence of patient narratives.
• Evaluate benefit-risk reasoning, scrutinizing the durability of conclusions in light of new events, and the realism of described management strategies.
• Identify and flag content that is clinically implausible or internally inconsistent, distinguishing these from legitimate clinical variation.
• Provide structured, guideline-based written rationales that clearly explain the validity or limitations of clinical interpretations for a non-clinical audience.

Preferred Qualifications

• Specialist registration or board certification in medical oncology and/or haematology, with 5+ years of post-training clinical experience.
• Direct involvement in clinical trials as investigator, sub-investigator, or sponsor-side medical monitor, safety physician, or clinical development physician.
• Proficiency with CTCAE grading, relevant response criteria (RECIST, Lugano, IMWG, IWCLL, ELN), and outcome endpoints (ORR, DoR, PFS, OS, MRD).
• Hands-on experience with trial documents such as protocols, investigator brochures, CSRs, safety narratives, or DSMB/IDMC materials.
• Demonstrated excellence in written communication, with clear, structured explanations of clinical reasoning tailored for non-clinical readers.
• Previous roles in medical monitoring or as medical director on oncology or haematology programmes, and committee participation (IDMC, DSMB, adjudication, or independent review committees).
• Peer-reviewed publication record or authorship on clinical trial manuscripts, with any exposure to AI-assisted clinical review tools seen as a plus.